These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 18693269)

  • 1. Multivalency: the hallmark of antibodies used for optimization of tumor targeting by design.
    Deyev SM; Lebedenko EN
    Bioessays; 2008 Sep; 30(9):904-18. PubMed ID: 18693269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and biodistribution of genetically-engineered antibodies.
    Colcher D; Pavlinkova G; Beresford G; Booth BJ; Choudhury A; Batra SK
    Q J Nucl Med; 1998 Dec; 42(4):225-41. PubMed ID: 9973838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibodies and gene therapy: teaching old 'magic bullets' new tricks.
    Sanz L; Blanco B; Alvarez-Vallina L
    Trends Immunol; 2004 Feb; 25(2):85-91. PubMed ID: 15102367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of dual-variable-domain immunoglobulin molecules for dual-specific targeting.
    Gu J; Ghayur T
    Methods Enzymol; 2012; 502():25-41. PubMed ID: 22208980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bispecific antibodies for cancer therapy.
    Chames P; Baty D
    Curr Opin Drug Discov Devel; 2009 Mar; 12(2):276-83. PubMed ID: 19333873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors.
    Beckman RA; Weiner LM; Davis HM
    Cancer; 2007 Jan; 109(2):170-9. PubMed ID: 17154393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bispecific antibodies for cancer therapy.
    Hollander N
    Immunotherapy; 2009 Mar; 1(2):211-22. PubMed ID: 20635943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PH1-derived bivalent bibodies and trivalent tribodies bind differentially to shed and tumour cell-associated MUC1.
    Schoonooghe S; Burvenich I; Vervoort L; De Vos F; Mertens N; Grooten J
    Protein Eng Des Sel; 2010 Sep; 23(9):721-8. PubMed ID: 20616115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant bispecific antibodies for cellular cancer immunotherapy.
    Müller D; Kontermann RE
    Curr Opin Mol Ther; 2007 Aug; 9(4):319-26. PubMed ID: 17694444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineered affinity proteins for tumour-targeting applications.
    Friedman M; Ståhl S
    Biotechnol Appl Biochem; 2009 May; 53(Pt 1):1-29. PubMed ID: 19341363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current perspectives of bispecific antibody-based immunotherapy.
    Talac R; Nelson H
    J Biol Regul Homeost Agents; 2000; 14(3):175-81. PubMed ID: 11037049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Bispecific antibodies: what future?].
    Pèlegrin A; Robert B
    Med Sci (Paris); 2009 Dec; 25(12):1155-8. PubMed ID: 20035697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant bispecific antibodies for the targeting of adenoviruses to CEA-expressing tumour cells: a comparative analysis of bacterially expressed single-chain diabody and tandem scFv.
    Korn T; Nettelbeck DM; Völkel T; Müller R; Kontermann RE
    J Gene Med; 2004 Jun; 6(6):642-51. PubMed ID: 15170735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineered antibodies.
    Hudson PJ; Souriau C
    Nat Med; 2003 Jan; 9(1):129-34. PubMed ID: 12514726
    [No Abstract]   [Full Text] [Related]  

  • 15. Optimizing properties of antireceptor antibodies using kinetic computational models and experiments.
    Harms BD; Kearns JD; Su SV; Kohli N; Nielsen UB; Schoeberl B
    Methods Enzymol; 2012; 502():67-87. PubMed ID: 22208982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Therapeutic monoclonal antibodies: a little history, a lot of engineering, and... some clinical successes].
    Siberil S; Dutertre CA; Boix C; Teillaud JL
    Transfus Clin Biol; 2005 Jun; 12(2):114-22. PubMed ID: 15907389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules.
    Adams GP; Schier R; McCall AM; Simmons HH; Horak EM; Alpaugh RK; Marks JD; Weiner LM
    Cancer Res; 2001 Jun; 61(12):4750-5. PubMed ID: 11406547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cationization of monoclonal antibodies: another step towards the "magic bullet"?
    Vaisitti T; Deaglio S; Malavasi F
    J Biol Regul Homeost Agents; 2005; 19(3-4):105-12. PubMed ID: 16602624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal antibodies as targeting and therapeutic agents: prospects for liver transplantation, hepatitis and hepatocellular carcinoma.
    Luk JM; Wong KF
    Clin Exp Pharmacol Physiol; 2006; 33(5-6):482-8. PubMed ID: 16700883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Target therapy of cancer: implementation of monoclonal antibodies and nanobodies.
    Majidi J; Barar J; Baradaran B; Abdolalizadeh J; Omidi Y
    Hum Antibodies; 2009; 18(3):81-100. PubMed ID: 19729803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.